南京伟思医疗科技股份有限公司 独立董事关于第三届董事会第十四次会议 相关事项的独立意见 根据《上海证券交易所科创板股票上市规则》《上市公司独立董事规则》等法 律法规、规范性文件以及《南京伟思医疗科技股份有限公司章程》《南京伟思医疗 科技股份有限公司独立董事工作制度》等的规定，我们作为南京伟思医疗科技股份 有限公司（以下简称"公司"）的独立董事，本着审慎、负责的态度，基于独立判 断的原则，经认真审阅相关材料，现就公司第三届董事会第十四次会议相关事项发 表独立意见如下： 一、关于公司 2023 年半年度募集资金存放和实际使用情况的独立意见 经核查，公司独立董事认为，公司 2023 年半年度募集资金的存放和使用符合 中国证监会、上海证券交易所关于上市公司募集资金存放和使用的相关监管要求， 对募集资金进行了专户存储和专项使用，不存在募集资金存放和使用违规的的行为， 不存在损害股东利益的情形。公司所披露的募集资金存放和使用情况信息与实际情 况一致，如实履行了信息披露义务。 因此，我们一致同意公司《关于公司 2023 年半年度募集资金存放与实际使用 情况的专项报告的议案》。 二、关于使用暂时闲置自有资金购买理财产品的独立 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2023-054 南京伟思医疗科技股份有限公司 第三届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 南京伟思医疗科技股份有限公司（以下简称"公司"）第三届监事会第十三 次会议通知于 2023 年 8 月 18 日以书面方式向全体监事发出。会议于 2023 年 8 月 28 日以现场结合通讯方式在公司会议室召开。本次会议由监事会主席胡平先 生主持，本次会议应出席会议监事 3 人，实际出席会议监事 3 人,本次会议的召 开符合《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》等相 关法律、行政法规、规范性文件及《南京伟思医疗科技股份有限公司章程》（以 下简称"《公司章程》"）的有关规定。 二、监事会会议审议情况 （一）审议通过《关于公司 2023 年半年度报告及其摘要的议案》 经审议，全体监事会认为：公司 2023 年半年度报告的编制和审议程序符合 相关法律法规及《公司章程》等内部规章制度的规定；公司 2023 ...

综上，我们一致同意将本项议案提交公司第三届董事会第十四次会议审议。 南京伟思医疗科技股份有限公司 独立董事关于第三届董事会第十四次会议 相关事项的事前认可意见 根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》《上 市公司独立董事规则》等法律、法规及规范性文件以及《南京伟思医疗科技股份 有限公司章程》《南京伟思医疗科技股份有限公司独立董事工作制度》等相关规 定，我们作为南京伟思医疗科技股份有限公司（以下简称"公司"）的独立董事， 对拟提交公司第三届董事会第十四次会议审议的下列事项进行了认真的事前审 核，现发表事前认可意见如下： 一、关于 2023 年度日常关联交易额度预计的事前认可意见 经核查，公司独立董事认为：公司 2023 年度预计发生的关联交易事项为公 司日常关联交易，为日常经营活动所必需，定价遵循市场公允定价原则，不存在 损害公司及全体股东尤其是中小股东合法权益的情形，不会对公司独立性产生影 响，不会对关联方形成依赖。 独立董事：肖俊方、吴家璐、蔡卫华 2023 年 8 月 28 日 （以下无正文） （此页无正文,为《南京伟思医疗科技股份有限公司独立董事关于第三届董 事会第十四次会议相关 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2023-055 南京伟思医疗科技股份有限公司 关于参加 2023 年半年度医疗器械及医疗设备专场集 体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 9 月 4 日(星期一)下午 16:00 前通过邮件、电话等形式将 需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普遍关 注的问题进行回答。 南京伟思医疗科技股份有限公司（以下简称"公司"）已于 2023 年 8 月 29 日披露《2023 年半年度报告》，为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状况、发展理念，公司参与了由上交所主办的 2023 半 年度医疗器械及医疗设备专场集体业绩说明会，此次活动将采用视频和网络文字 互 动 的 方 式 举 行 ， 投 资 者 可 登 录 上 海 证 券 交 易 所 上 证 路 演 中 心 （http://roadshow.sseinfo.com/）参与线上互动交流。 会议线 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2023-049 南京伟思医疗科技股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 按照《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有 关规定，南京伟思医疗科技股份有限公司（以下简称"公司"或"本公司"）董 事会编制了 2023 年半年度（以下简称"报告期内"）募集资金存放与实际使用 情况的专项报告如下： 一、募集资金基本情况 （一）实际募集资金金额及资金到账情况 根据中国证券监督管理委员会《关于同意南京伟思医疗科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2020〕1213 号）文件核准，公司向社 会公众发行人民币普通股（A 股）17,086,667 股，每股面值人民币 1.00 元，每 股发行价格为人民币 67.58 元，共募集资金 1,154,716,955.86 元，扣除应付发 行费用 9 ...

Dividend Distribution - The company plans to distribute a cash dividend of RMB 6.876 per 10 shares, totaling approximately RMB 46.91 million, based on a total share capital of 68,222,419 shares after buybacks[5]. - The total cash dividend for 2022 amounts to RMB 61.77 million, representing 65.83% of the net profit attributable to shareholders[6]. - The company has repurchased shares worth RMB 14.86 million during the year, which is included in the cash dividend calculation[6]. - The company does not plan to increase capital reserves or issue bonus shares, with remaining undistributed profits carried forward[5]. Financial Performance - The company's operating revenue for 2022 was CNY 321,621,418.85, a decrease of 25.21% compared to CNY 430,044,459.65 in 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 93,825,897.99, down 47.23% from CNY 177,811,885.55 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was CNY 76,590,650.79, a decline of 48.99% from CNY 150,144,023.66 in 2021[25]. - The cash flow from operating activities for 2022 was CNY 86,168,338.86, down 45.24% from CNY 157,367,012.60 in 2021[25]. - The basic earnings per share for 2022 was CNY 1.3739, a decrease of 47.19% compared to CNY 2.6016 in 2021[26]. - The total assets at the end of 2022 were CNY 1,684,216,383.26, an increase of 2.77% from CNY 1,638,742,744.28 at the end of 2021[25]. - The net assets attributable to shareholders at the end of 2022 were CNY 1,528,547,226.43, a slight decrease of 0.29% from CNY 1,533,062,870.88 at the end of 2021[25]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 19.07% in 2022, up 4.30 percentage points from 14.77% in 2021[26]. - The company submitted 98 patent applications during the reporting period, with 95 patents granted, including 24 invention patents[36]. - The company has developed a compact high-voltage medical power supply for magnetic stimulation products, achieving a continuous output of 100Hz pulse frequency and 6Tesla magnetic field strength[83]. - The company has filed for 40 invention patents in the rehabilitation robotics field, with products covering lower and upper limb rehabilitation training expected to be fully launched in 2022[85]. - The company is actively researching functional electrical stimulation and intelligent electrical stimulation technologies to enhance rehabilitation capabilities[89]. Market Expansion and Strategy - Future outlook includes expanding product lines in pelvic floor rehabilitation and cognitive function recovery, targeting a market growth of 15% annually[15]. - Market expansion strategies involve entering Southeast Asian markets, aiming for a 10% market share within two years[15]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in robotic rehabilitation technologies[15]. - The company aims to improve operational efficiency by reducing production costs by 8% through automation and process optimization[15]. - The company is focusing on the medical aesthetics energy source market, with a diverse product matrix covering gynecology, dermatology, and medical beauty, targeting to become a top brand in China's medical aesthetics energy source market[45]. Operational Risks and Compliance - The company has faced various operational risks, which are detailed in the report[4]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has received a standard unqualified audit report from Tianheng Accounting Firm[5]. - The company’s board of directors and management have confirmed the accuracy and completeness of the annual report[4]. - The company is actively monitoring industry policies and regulations to adapt its strategic layout in response to potential risks[120]. Talent and Management - The company has implemented a talent incentive mechanism, including an "Elite Talent Program" and stock incentive plans, to enhance team stability and cohesion[46]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to RMB 700.75 million[200]. - The company is implementing a talent cultivation program to develop management and specialized personnel, enhancing overall human resource quality[176]. - The company has seen personnel changes, with three executives resigning due to personal reasons, including the Deputy General Manager and Chief Technology Officer[199]. Product Development and Innovation - The company is focusing on rehabilitation medical devices utilizing electrical stimulation, electrophysiology, and magnetic stimulation technologies[14]. - The introduction of the MyOnyx series, a new line of biofeedback devices, is expected to generate $2 million in revenue within the first year of launch[15]. - The company achieved a significant milestone by being recognized as a national-level specialized and innovative "little giant" enterprise in 2022[91]. - The company is developing next-generation magnetic stimulation products aimed at various medical applications, including obstetrics and rehabilitation[98]. Financial Guidance and Future Outlook - The financial guidance for the next quarter anticipates a revenue increase of 20% year-over-year, driven by new product launches and market expansion[15]. - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming for $625 million[194]. - The company plans to enhance its research and development capabilities, targeting high-end and high-growth markets, and aims to achieve breakthroughs in technologies such as electrical stimulation and rehabilitation robotics[170].

Financial Performance - In Q1 2023, the total revenue reached CNY 95,539,491.61, representing a year-on-year increase of 76.57%[5] - The net profit attributable to shareholders was CNY 30,081,694.57, up 76.85% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 26,468,101.27, showing a significant increase of 190.81% year-on-year[5] - Basic earnings per share were CNY 0.4406, reflecting a growth of 77.02%[6] - The total revenue for Q1 2023 was CNY 95,539,491.61, representing a 76.6% increase compared to CNY 54,107,297.63 in Q1 2022[19] - The net profit for Q1 2023 was CNY 30,081,694.57, which is a 76.9% increase from CNY 17,009,682.26 in Q1 2022[20] - The basic earnings per share for Q1 2023 was CNY 0.4406, compared to CNY 0.2489 in Q1 2022, reflecting a 77.0% increase[21] Expenses and Costs - Research and development expenses totaled CNY 15,218,176.47, which accounted for 15.93% of total revenue, a decrease of 13.30 percentage points[6] - The total operating costs for Q1 2023 were CNY 71,236,099.36, up from CNY 48,757,775.32 in Q1 2022, indicating a 46.0% increase[19] - The cash paid for purchasing goods and services in Q1 2023 was CNY 33,875,389.57, compared to CNY 16,103,900.51 in Q1 2022, which is a 109.0% increase[22] - The cash paid to employees in Q1 2023 was CNY 49,138,726.29, an increase from CNY 39,188,076.44 in Q1 2022, representing a 25.4% rise[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,721,089,251.57, an increase of 2.19% from the end of the previous year[6] - Total assets as of March 31, 2023, amounted to CNY 1,721,089,251.57, an increase from CNY 1,684,216,383.26 at the end of 2022[15] - Cash and cash equivalents decreased slightly to CNY 1,241,734,956.78 from CNY 1,248,127,080.91[15] - Accounts receivable decreased to CNY 20,378,378.62 from CNY 21,109,272.25, indicating a reduction of approximately 3.46%[15] - Inventory increased to CNY 38,582,312.84 from CNY 34,835,234.85, reflecting an increase of about 10.00%[15] - Total current liabilities rose to CNY 140,512,900.29 from CNY 129,243,639.61, representing an increase of approximately 8.83%[16] - Non-current assets totaled CNY 402,254,702.91, up from CNY 365,006,831.25, marking an increase of about 10.19%[16] - The total liabilities as of Q1 2023 were CNY 167,225,222.37, compared to CNY 155,669,156.83 in the previous year, showing a 7.4% increase[17] - The total equity attributable to shareholders as of Q1 2023 was CNY 1,553,864,029.20, up from CNY 1,528,547,226.43 in Q1 2022, indicating a 1.7% increase[17] - The deferred income tax liabilities decreased to CNY 532,680.04 from CNY 550,724.95, reflecting a 3.3% decrease[17] Cash Flow - Cash flow from operating activities was CNY 11,154,972.16, with no applicable year-on-year comparison[5] - The net cash flow from operating activities for Q1 2023 was $11,154,972.16, a significant improvement compared to a negative cash flow of $4,026,720.88 in Q1 2022, representing a turnaround of over 375%[23] - The total cash outflow from financing activities was $5,159,439.43, compared to $676,260.23 in Q1 2022, indicating an increase of over 663%[23] - The company reported a total cash outflow from operating activities of $113,087,236.15, which is an increase of approximately 34% compared to $84,452,766.78 in Q1 2022[23] - The cash flow from investment activities included cash received from the recovery of investments amounting to $655,000,000.00, down from $1,131,700,000.00 in the previous year, a decrease of about 42%[23] - The company paid $18,593,403.16 for the acquisition of fixed assets and intangible assets, which is an increase from $10,782,947.36 in Q1 2022, reflecting a growth of approximately 72%[23] Shareholder Information - The company has a total of 5,080 common shareholders as of the report date[12] - The top shareholder, Wang Zhiyu, holds 39.29% of the shares, totaling 26,961,547 shares[12] Strategic Developments - The company has not disclosed any significant new strategies or product developments in this report[14]

证券代码：688580 证券简称：伟思医疗 公告编号：2023-019 南京伟思医疗科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 05 月 10 日(星期三)下午 14:00-15:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 28 日(星期五)至 05 月 09 日(星期二)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@vishee.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 南京伟思医疗科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日发布《2022 年年度报告》和《2023 年第一季度报告》，为便于广大投资者更 全面深入地了解公司 2022 年度、2023 年第一 ...

VISHEE 南京伟思医疗科技股份有限公司 投资者关系活动记录表 （2022 年 3 月） 证券代码：688580 证券简称：伟思医疗 | --- | --- | |----------------------|------------------------------------------------------------------------| | | | | 活动时间： | | | 2022/03/01 | 10:00-11:00 | | 2022/03/03 | 10:00-12:00 | | 2022/03/04 | 14:00-15:00 | | 2022/03/15 | 10:00-12:00 | | 2022/03/28 | 10:00-11:00 | | 2022/03/30 | 14:00-15:00 | | 活动地点： | | | 南京市雨花台区宁双路 | 19 号 9 栋公司会议室 | | 参加单位名称： | | | | 方正证券、清水源、国寿安保基金、天虫资本、拓璞基金、泰达宏利、上 | | | 海涌津投资、中信建投、财通基金、兴业基金、新华基金、璞远资产、兴业资 | | | ...

VISHEE #恩 南京伟思医疗科技股份有限公司 投资者关系活动记录表 （2022 年 4 月） 证券代码：688580 证券简称：伟思医疗 活动时间： 2022/04/27 20:00-21:00 2022/04/28 10:00-11:00 2022/04/29 09:00-10:00 2022/04/29 10:00-11:00 2022/04/29 13:00-14:00 2022/04/29 14:00-15:00 2022/04/29 15:00-16:00 活动地点： 南京市雨花台区宁双路 19 号 9 栋公司会议室 参加单位名称： 长青基业、陕西海拓、钧荷资产、中信建投、苏豪投资、铭丰资本、国寿 安保基金、万方、上汽投资、璞远资产、中国人保资产、深圳瑞福资产、西藏 源乘投资、朴易投资、中欧基金、上海易正朗投资、凯石基金、HBM PARTNERS HONGKONG、宝盈基金、玖鹏资产、华泰证券、国泰君安、进化论资产、同泰基 金、东方医药、上银基金、上海顶天投资、域秀资产、中车资本、Yunqi Path、 瀚伦投资、深圳清水源投资、固禾资产、臻宜投资、朴易资产、中信保诚、湘 楚资产、博裕资本、泰信 ...